The notices it replaced
- Reissues: PAR-15-096 Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH3)
Replaced by PAR-20-314.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $697,450 in first-year total cost, median $348,725.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-Z (J2)]1
- Special Emphasis Panel[ZCA1 RPRB-Z (O1)]1
Most frequent institutions
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- JOHNS HOPKINS UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Evaluation of commercially available prostate cancer assays to accelerate novel applications in active surveillance1UH3CA234196-01 | LIN, DANIEL W.ZHENG, YINGYE | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $365,856 | ZCA1 |
| 2019 | Developing a CLIA compliant LDT for detecting plasma piR-Ls/pfeRNAs to distinguish benign and malignant lung nodules1UH3CA239137-01 | BROCK, MALCOLM VMEI, YUPING | JOHNS HOPKINS UNIVERSITY, MD | $331,594 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.